Clinical Dilemmas in Women's Health: Using Current Evidence to Answer Questions about Hormonal Contraception in the Middle Years

Sidney S , Siscovick DS , Petitti DB et al. Myocardial infarction and use of low-dose oral contraceptives: A pooled analysis of 2 U.S. studies. Circulation, 1998; 98:1058–1063.

Schwartz SM , Petitti DB , Siscovick DS et al. Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies. Stroke, 1998; 29:2277–2284.

Oelkers W , Foidart JM , Dombrovicz N , Welter A , Heithecker R . Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab, 1995; 80:1816–1821.

Cardiovascular disease and steroid hormone contraception. Report of a WHO Scientific Group. World Health Organ Tech Rep Ser, 1998; 877:i–vii–1–89.

Heinemann LA , Assmann A , DoMinh T , Garbe E . Oral progestogen-only contraceptives and cardiovascular risk: Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Eur J Contracept Reprod Health Care, 1999; 4:67–73.

Tanis BC , van den Bosch MAAJ , Kemmeren JM et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med, 2001; 345:1787–1793.

Kaunitz A . Hormonal contraception in women of older reproductive age. N Engl J Med, 2008; 358:1262–1270.

Petitti D . Combination estrogen-progestin oral contraceptives. N Engl J Med, 2003; 349:1443–1450.

Audet M , Moreau M , Koltun WD et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive. JAMA, 2001; 285:2347–2354.

Contraceptive Technology website. www.contraceptivetechnology.org/table.html. 2008 March 5.

Zieman M , Guillebaud J , Weisberg G et al. Integrated summary of contraceptive efficacy with the Ortho Evra/Evra transdermal system. Fertil Steril, 2001; 76–S19[Abstract O-48].

Petitti DB , Piaggo G , Mehta S et al. Steroid hormone contraception and bone mineral density: A cross-sectional study in an international population. Obstet Gynecol, 2000; 95:736–744.

Orr-Walker BJ , Evans MC , Ames RW et al. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal postmenopausal women. Clin Endocrinol, 1998; 49:615–618.

Scholes D , LaCroix A , Ichikawa LE et al. Injectable hormone contraception and bone density: Results from a prospective study. Epidemiology, 2002; 13:581–587.

Beerthuizen R , van Beeck A , Massai R et al. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod, 2000; 15:118–122.

Bennink HJTC . The pharmacokinetics and pharmacodynamics of Implanon, a single- rod etonogestrel contraceptive implant. Eur J Contracept Reprod Health Care, 2000; 5,Suppl 2:12–20.

Walker AM . Newer oral contraceptives and the risk of venous thromboembolism. Contraception, 1998; 57:169–181.

Hennessy S , Berlin JA , Kinman JL , Margolis DJ , Marcus SM , Strom BL . Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: A meta-analysis and formal sensitivity analysis. Contraception, 2001; 64:125–133.

Kemmeren JM , Algra A , Grobbee DE . Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. BMJ, 2001; 323:131–134.

Department of Health and Human Services. The health benefits of smoking cessation: A report of the Surgeon General, 1990. Washington, DC: Government Printing Office, 1990.

Critchley JA , Capewell S . Mortality risk reduction associated with smoking cessation in patients with coronary heart disease: A systematic review. JAMA, 2003; 290:86–97.

Marchbanks PA , McDonald JA , Wilson HG et al. Oral contraceptives and the risk of breast cancer. N Engl J Med, 2002; 346:2025–2032.

ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol, 2006; 107:1453–1472.

MacClellan LR , Giles W , Cole J et al. Probable migraine with visual aura and risk of ischemic stroke: The Stroke Prevention in Young Women Study. Stroke, 2007; 38:2438–2445.

Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders. Cephalalgia, 2004; 24:1:9–160.

Gervil M , Ulrich V , Olesen J , Russell MB . Screening for migraine in the general population: Validation of a simple questionnaire. Cephalalgia, 1998; 18:342–348.

Becker WJ . Use of oral contraceptives in patients with migraine. Neurology, 1999; 53,Suppl 1:S19–S25.

Michaëlsson K , Baron JA , Farahmand BY , Persson I , Ljunghall S . Oral contraceptive use and risk of hip fracture: A case-control study. Lancet, 1999; 353:1481–1484.

Callaghan WM , Berg CJ . Pregnancy-related mortality among women aged 35 years and older, United States, 1991–1997. Obstet Gynecol, 2003; 102:1015–1021.

Romp ER , le Cessie S , Rosendaal SR , Doggen CJM . Risk of venous thrombosis: Obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol, 2007; 139:289–296.

Wu O , Greer IA . Is screening for thrombophilia cost effective? Curr Opin Hematol, 2007; 14:500–503.

Jick SS , Kaye JA , Russmann S , Jick J . Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 mcg ethinyl estradiol. Contraception, 2006; 73:223–228.

Van den Heuvel MW , van Bragt AJM , Alnabawy AKM , Kaptein MCJ . Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: The vaginal ring, the transdermal patch, and an oral contraceptive. Contraception, 2005; 72:168–174.